Evidence map›Paper›PMID 30696271›Full record

ArticleThe American journal of psychiatry2019

Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia.

Roscoe O Brady, Irene Gonsalvez, Ivy Lee, Dost Öngür, Larry J Seidman, Jeremy D Schmahmann, Shaun M Eack, Matcheri S Keshavan, Alvaro Pascual-Leone, Mark A Halko

4 registry-linked trialsAbstract read
In one paragraph

Article in The American journal of psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 216 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
216citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04853485 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Repetitive Transcranial Magnetic Stimulation in Subjects With Early Psychosis and The Functional Connectivity Biotypes

TypeinterventionalSponsorShanghai Jiao Tong University School of MedicineRan2020 to 2024Enrolled300ConditionsSchizophrenia, Psychosis, First Episode Psychosis, Clinical High RiskArmsrepetitive transcranial magnetic stimulation (rTMS)
NCT04859504 nacompletednot on this mapstarted 2021, after this paper: background citation

Dual-channel Transcranial Alternating Current Stimulations Targeting Negative Symptoms in Schizophrenia Patients: a Randomized Clinical Trial

TypeinterventionalSponsorShanghai Mental Health CenterRan2021 to 2024Enrolled60ConditionsSchizophrenia, Transcranial Alternating Current Stimulations, Negative SymptomsArmstranscranial alternating current stimulation (NE Starstim)
NCT05343598 narecruitingnot on this mapstarted 2021, after this paper: background citation

Empirical Validation of a Cerebellar-cortical Hallucination Circuit

TypeinterventionalSponsorMclean HospitalRan2021 to 2026Enrolled68ConditionsSchizophrenia, Schizo Affective DisorderArmsRepetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
NCT06542640 narecruitingnot on this mapstarted 2024, after this paper: background citation

Identifying Mechanisms of Response to Therapeutic Intervention in Clinical High Risk (CHR) for Psychosis: a Bridge to Treatment

TypeinterventionalSponsorBeth Israel Deaconess Medical CenterRan2024 to 2027Enrolled300ConditionsPsychosis, Schizophrenia-Like, Healthy ControlsArmsMb-rt-fMRI-NFB, Sham mb-rt-fMRI-NFB, rTMS, Sham rTMS
3 · Its place in the literature

Who cites it

216 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. A Systematic Review of Noninvasive Brain Stimulation for Opioid Use Disorder.Neuromodulation : journal of the International Neuromodulation Society · 2020
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

156 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Roscoe O BradyFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Irene GonsalvezFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Ivy LeeFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Dost ÖngürFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Larry J SeidmanFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Jeremy D SchmahmannFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Shaun M EackFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Matcheri S KeshavanFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Alvaro Pascual-LeoneFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).
Mark A HalkoFrom the Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Brady, Lee, Seidman, Keshavan); the Schizophrenia and Bipolar Disorders Program, McLean Hospital, Belmont, Mass. (Brady, Öngür); Harvard Medical School, Boston (Brady, Öngür); St. Elizabeth's Medical Center, Boston (Gonsalvez); the Department of Neurology, Ataxia Unit, Cognitive Behavioral Neurology Unit, and Laboratory for Neuroanatomy and Cerebellar Neurobiology, Massachusetts General Hospital and Harvard Medical School, Boston (Schmahmann); the Department of Psychiatry and the School of Social Work, University of Pittsburgh (Eack); and the Berenson-Allen Center for Noninvasive Brain Stimulation and Division for Cognitive Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston (Pascual-Leone, Halko).

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Brain Imaging, Cognitive Enhancement and Early SchizophreniaR01MH092440 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KESHAVAN, MATCHERI S. · 2012 to 2016
$3.1M
Dose Dependent Response of Cerebellar Transcranial Magnetic StimulationR01MH111868 · NIMH · MCLEAN HOSPITAL · PI HALKO, MARK A · 2016 to 2019
$1.7M
Longitudinal Imaging Studies in Bipolar DisorderK23MH100623 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BRADY, ROSCOE O. · 2014 to 2018
$883k
Research and Mentoring on Brain and Peripheral Bioenergetics in SchizophreniaK24MH104449 · NIMH · MCLEAN HOSPITAL · PI ONGUR, DOST · 2015 to 2019
$749k
NCRR NIH HHS UL1 RR025758NIMH NIH HHS K23 MH100623NIMH NIH HHS K24 MH104449NIMH NIH HHS R01 MH092440NIMH NIH HHS R01 MH111868
6 · The paper itself

Abstract

objectiveThe interpretability of results in psychiatric neuroimaging is significantly limited by an overreliance on correlational relationships. Purely correlational studies cannot alone determine whether behavior-imaging relationships are causal to illness, functionally compensatory processes, or purely epiphenomena. Negative symptoms (e.g., anhedonia, amotivation, and expressive deficits) are refractory to current medications and are among the foremost causes of disability in schizophrenia. The authors used a two-step approach in identifying and then empirically testing a brain network model of schizophrenia symptoms.

methodsIn the first cohort (N=44), a data-driven resting-state functional connectivity analysis was used to identify a network with connectivity that corresponds to negative symptom severity. In the second cohort (N=11), this network connectivity was modulated with 5 days of twice-daily transcranial magnetic stimulation (TMS) to the cerebellar midline.

resultsA breakdown of connectivity in a specific dorsolateral prefrontal cortex-to-cerebellum network directly corresponded to negative symptom severity. Restoration of network connectivity with TMS corresponded to amelioration of negative symptoms, showing a statistically significant strong relationship of negative symptom change in response to functional connectivity change.

conclusionsThese results demonstrate that a connectivity breakdown between the cerebellum and the right dorsolateral prefrontal cortex is associated with negative symptom severity and that correction of this breakdown ameliorates negative symptom severity, supporting a novel network hypothesis for medication-refractory negative symptoms and suggesting that network manipulation may establish causal relationships between network markers and clinical phenomena.

Indexed as

beta-LactamasesCerebellumFemaleHumansMaleModels, BiologicalNerve NetNeuroimagingPrefrontal CortexPsychiatric Status Rating ScalesSchizophreniaSeverity of Illness IndexTranscranial Magnetic StimulationYoung Adultbeta-lactamase MIR-1, Enterobacter cloacaebeta-LactamasesBrain Imaging TechniquesSchizophrenia

Identifiers

PMID30696271
PMCPMC6760327

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.